ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
67,116.66
0.05%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Atossa Therapeutics Inc (ATOS)

  7. Atossa Therapeutics Inc (ATOS) 뉴스

ATOS

Atossa Therapeutics (ATOS)

Atossa Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ATOS
일자시간출처헤드라인심볼기업
2024/05/1521:30GlobeNewswire Inc.Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
2024/05/1505:46Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:ATOSAtossa Therapeutics Inc
2024/05/1405:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATOSAtossa Therapeutics Inc
2024/05/1322:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATOSAtossa Therapeutics Inc
2024/05/1322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
2024/05/1321:50GlobeNewswire Inc.Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
2024/05/1022:04Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ATOSAtossa Therapeutics Inc
2024/05/1022:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
2024/05/0721:30GlobeNewswire Inc.Atossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesNASDAQ:ATOSAtossa Therapeutics Inc
2024/04/2921:30GlobeNewswire Inc.Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
2024/04/1521:30GlobeNewswire Inc.Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
2024/04/1121:30GlobeNewswire Inc.Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
2024/04/1000:59GlobeNewswire Inc.Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
2024/04/0205:00GlobeNewswire Inc.Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
2024/03/1921:30GlobeNewswire Inc.Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer PatientNASDAQ:ATOSAtossa Therapeutics Inc
2024/03/1821:30GlobeNewswire Inc.Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsNASDAQ:ATOSAtossa Therapeutics Inc
2024/03/1221:30GlobeNewswire Inc.Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of DirectorsNASDAQ:ATOSAtossa Therapeutics Inc
2024/02/2222:30GlobeNewswire Inc.Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyNASDAQ:ATOSAtossa Therapeutics Inc
2024/02/0722:30GlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
2024/01/0922:30GlobeNewswire Inc.Atossa Therapeutics Issues Letter to ShareholdersNASDAQ:ATOSAtossa Therapeutics Inc
2023/12/0422:30GlobeNewswire Inc.Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorNASDAQ:ATOSAtossa Therapeutics Inc
2023/11/2022:30GlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
2023/11/1607:03Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ATOSAtossa Therapeutics Inc
2023/11/1606:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATOSAtossa Therapeutics Inc
2023/11/1606:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATOSAtossa Therapeutics Inc
2023/11/1323:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATOSAtossa Therapeutics Inc
2023/11/1323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
2023/11/1323:00GlobeNewswire Inc.Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
2023/11/0923:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
2023/11/0923:00GlobeNewswire Inc.Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of DirectorsNASDAQ:ATOSAtossa Therapeutics Inc
 검색 관련기사 보기:NASDAQ:ATOS

최근 히스토리

COIN
JWLGBP
KOSPI
006840
AK홀딩스
BIT
UB03SS
UniCredit Bank
NASDAQ
INGN
Inogen
BIT
USIG
Liquid In Grade Corp Bon...
BFNX
SMRUSD
Shimmer
NASDAQI
OMXNMCISKPI
OMX Nordic Mid Cap ISK PI
EU
BNS4B
Bnp Paribas null
LSE
NV50
Citi Fun 24
TSXV
KGL.H
KGL Resources
GATE
XCURUSDT
Curate
BIT
FEQD
Fidelity Europe Quality ...
EU
EUS3
WisdomTree Long USD Shor...
BOV
G2DD34
Godaddy
NASDAQ
ANZUW
Anzu Special Acquisition...
BIT
UC24DH
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유